We have developed a robust clinical and preclinical pipeline through a combination of internal discovery efforts and focused asset acquisition. The following chart summarizes our product pipeline.
Candidate & Indication
Additional proprietary programs from mapping and screening the MYC, AR, MYB, IRF4 and other TRNs
We may not be successful in identifying product candidates that can selectively modulate the specific oncogenic TRNs associated with such programs.